Apogee Therapeutics, Inc. cash flow to debt ratio of -2.57K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Apogee Therapeutics, Inc.'s free cash flow has decreased 34.97% from $-172.33M last year to $-232.60M, signaling decreasing performance

Apogee Therapeutics, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Apogee Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.01 today, signaling strengthened financials

Apogee Therapeutics, Inc. has a net cash position, so leverage is healthy.

Apogee Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Apogee Therapeutics, Inc. has insufficient data to evaluate this check.

Apogee Therapeutics, Inc.'s short-term assets of $741.36M exceed its short-term liabilities of $27.91M

Apogee Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Apogee Therapeutics, Inc.'s return on equity of -13.64%, is lower than 15.00%, indicating bad performance

Apogee Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Apogee Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

Apogee Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Apogee Therapeutics, Inc. has negative free cash flow, indicating cash burn

Apogee Therapeutics, Inc.'s yearly earnings has decreased 40.46% since last year from $-182.15M to $-255.84M, signaling decreasing performance

Apogee Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -25.22% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Apogee Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Apogee Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

Apogee Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

Apogee Therapeutics, Inc. has insufficient data to evaluate this check.

Apogee Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Apogee Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Apogee Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Apogee Therapeutics, Inc. has insufficient data to evaluate this check.

Apogee Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Apogee Therapeutics, Inc. has a price-to-book ratio of 8.50x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Apogee Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue